Capricor Therapeutics (CAPR) Free Cash Flow (2010 - 2026)

Capricor Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$34.4 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 369.02% year-over-year to -$34.4 million; the TTM figure through Mar 2026 stood at -$99.8 million (down 114.01% YoY), while the FY2025 annual figure was -$72.7 million, down 76.65% from the prior year.
• Free Cash Flow was -$34.4 million for Q1 2026 at Capricor Therapeutics, down from -$25.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $23.5 million in Q1 2022 to a low of -$34.4 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$10.1 million across 5 years, with a median of -$9.6 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Free Cash Flow soared 797.47% in 2022, then sank 369.02% in 2026.
• A 5-year view of Free Cash Flow shows it stood at -$7.6 million in 2022, then slumped by 59.99% to -$12.2 million in 2023, then retreated by 25.78% to -$15.3 million in 2024, then slumped by 65.07% to -$25.2 million in 2025, then plunged by 36.24% to -$34.4 million in 2026.
• The last three Free Cash Flow figures came in at -$34.4 million (Q1 2026), -$25.2 million (Q4 2025), and -$19.7 million (Q3 2025), per Business Quant data.